LePu Biopharma Co., Ltd.

This phase III trial compares an experimental drug called MRG003 with two standard treatments, cetuximab and methotrexate, in adults with recurrent or metastatic squamous cell carcinoma of the head and neck. Participants must have already tried and failed both a PD-1/PD-L1 inhibi…

This early-phase trial tests whether combining two experimental drugs, MRG003 and HX008, can safely shrink tumors in people with advanced solid cancers that carry a protein called EGFR. The study includes adults with non-small cell lung cancer, head and neck cancer, or nasopharyn…

This Phase 3 trial tests whether combining two drugs, MRG003 and pucotenlimab, works better than standard chemotherapy for people with nasopharyngeal cancer that has returned or spread. About 446 participants will be randomly assigned to receive either the new combo or one of thr…

This early-phase trial tests a new drug called MRG006A, combined with immunotherapy and targeted therapy, in 160 people with advanced hepatocellular carcinoma (a type of liver cancer) that cannot be treated with surgery. The study aims to check safety, find the right dose, and se…

This phase II trial tests whether combining two drugs—pucotenlimab (an immunotherapy) and becotatug vedotin (a targeted chemotherapy)—given before and after surgery can improve outcomes for people with locally advanced head and neck cancer. About 80 participants will receive eith…

This phase 2 trial is testing a treatment called cretostimogene grenadenorepvec, a modified virus designed to infect and destroy cancer cells, in 16 people with high-risk bladder cancer that has not responded to standard BCG therapy. The study aims to see if the treatment can mak…

This study tests an experimental drug called MRG006A in 343 adults with advanced solid tumors that have spread or cannot be removed. The drug is given through a vein. The main goals are to find the safest dose and see if the drug can shrink tumors. The trial is currently recruiti…